Canada's InMed Pharmaceuticals Q1 loss widens

What happened

InMed Pharmaceuticals, a Canadian drug developer, reported a wider fiscal first-quarter net loss while research and development spending fell. It expects its proposed merger with Mentari, still awaiting approval, to provide financing. Available cash is projected to fund operations into mid-November 2026.

Proposed

Global impact / market context

A widening loss while research spending falls shows the company is conserving cash to survive until the proposed Mentari merger closes. If that deal is delayed or fails, InMed may run short of money, forcing it to raise funds, cut costs further, or lose its Nasdaq listing.

Analyst inference

Small drug developers often rely on mergers or share sales to fund research before products earn revenue. InMed's plan to restore Nasdaq compliance through the Mentari deal places it among cash-constrained biotech firms whose futures hinge on deal approval and financing.

Analyst inference

What to watch

1. InMed expects the proposed Mentari merger to close in the fourth quarter of 2026, subject to conditions, and says the deal and financing should help regain Nasdaq compliance, though it offers no assurance. Confirmed
2. Watch whether the proposed merger gains approval and closes on schedule, since InMed ties its funding plans and Nasdaq compliance hopes to completion of the transaction. Proposed
3. Track InMed's research spending and cash balance, because lower research outlays suggest retrenchment and any funding shortfall could force new share sales that dilute existing investors. Analyst inference

Evidence

• Original source link unavailable